Haemophilus Influenzae Type B (Hib) Vaccine – Pipeline Assessment and Market Forecasts to 2019

The Haemophilus Influenzae Type b (Hib) Vaccine Market is Forecast to Show Low Growth up until 2019
By: Rajesh Gunnam
 
Feb. 10, 2012 - PRLog -- GlobalData’s analysis shows that the global Haemophilus Influenzae Type b (Hib) vaccine market stood at $757.9m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 9.3% to reach $1,181.5m in
2011. GlobalData forecasts that the global Hib vaccine market will grow at a CAGR of 2.3% over the next eight years to reach $1,414.9m by 2019. Vaccination programs by the World Health Organization (WHO) have spurted the vaccination coverage rate rendering a high growth rate in the Hib vaccines market in the historical period from 2006 to 2011. The Global Alliance for Vaccines and Immunization (GAVI) their Hib initiative (2005) promoted the use of Hib as a mandatory vaccine in national immunization programs in both developed and developing countries. The Hib vaccine market is expected to show low growth during the forecast period. This is primarily attributed to the availability of an adequate number of safe and effective vaccines in the Hib vaccine market and a high vaccine coverage rate. These vaccines are included in the national immunization programs of the seven major geographies: the US, France, Germany, Italy, Spain and the UK, and are cost effective as they are subsidized. However, the Hib vaccine is not mandatory for administration in Japan under their national immunization program which was implemented in December 2008.

The market is well served with monovalent vaccines like ActHIB (Sanofi) and PedvaxHIB (Merck). Combination vaccines, such as Pentacel (Sanofi), ComvaxHIB (Merck), are also preferred by vaccine providers as they provide immunity against several infectious childhood diseases with only one shot of vaccine, reducing the discomfort and pain felt by the child during vaccination. Hiberix (GlaxoSmithKline) is another vaccine approved for booster dose in the Hib vaccine market. Menitorix (GlaxoSmithKline) and Vaxem HIB (GlaxoSmithKline) are other vaccines that are available in the European market. Menitorix is a combined vaccine which provides immunity against both meningitis and Hib. On the other hand, Vaxem is a monovalent vaccine. The availability of vaccines is non-uniform in the European Hib vaccines market. The cost of therapy for monovalent vaccines for the prophylaxis of Hib is lower than that of the combined vaccines.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData found the unmet need in Hib vaccine market to be low. This may be attributed to the availability of various monovalent and combined vaccines for the prophylaxis of Hib diseases. Also, as these vaccines have a proven efficacy and safety in preventing Hib diseases, they are adequately serving the market. The cost effectiveness of these vaccines is also high as they are mandatory vaccines and are therefore subsidized by the governments. However, in Japan, Hib vaccines were included in the national immunization program in 2008 and are given on request only. The following figure depicts the unmet need in the Hib monovalent vaccine market.

GlobalData, the industry analysis specialist, has released its new report, “Haemophilus Influenzae Type B (Hib) Vaccine - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Haemophilus influenzae type B vaccine Therapeutics market. The report identifies the key trends shaping and driving the global Haemophilus influenzae type B vaccine Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Haemophilus influenzae type B vaccine Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haem...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.
End
Source:Rajesh Gunnam
Email:***@globaldata.com
Posted By:***@globaldata.com Email Verified
Zip:EC4Y 0AN
Tags:Haemophilus Influenzae Type B, HIB, Pharmaceuticals_and_healthcare
Industry:Health
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GlobalData PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share